CD274 and colorectal carcinoma: ATOMIC study (NCT02912559) (84) is exploring the efficacy of PD-L1 inhibitors (atezolizumab) combined with chemotherapy versus adjuvant chemotherapy in dMMR stage III CRC, with the primary endpoint being disease-free survival.